{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001229","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.521178+00:00","generated_at":"2026-05-28T03:01:44.876483+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aquestive provides business update; on track to submit Anaphylm NDA in Q1 2025; cash ~$70M","bullets":["On track to submit Anaphylm (epinephrine) Sublingual Film NDA to FDA in Q1 2025; potential approval/launch as early as Q1 2026.","Successfully completed pre-IND meeting for AQST-108 (epinephrine) Topical Gel; Phase 2a in alopecia areata to begin Q2 2025.","Unaudited cash and cash equivalents approximately $70 million as of Dec 31, 2024.","Libervant (diazepam) Buccal Film received FDA approval for ages 2-5 and Orphan Drug Exclusivity until April 2031.","CEO outlines 2025 focus: Anaphylm launch prep, ex-U.S. strategy, AQST-108 Phase 2a, Libervant expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001229","json":"https://secwatch.observer/filing/0001628280-25-001229.json","markdown":"https://secwatch.observer/filing/0001628280-25-001229.md","text":"https://secwatch.observer/filing/0001628280-25-001229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/0001628280-25-001229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqst-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:01:44.876483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}